Roche has opened a new $500 million biologics manufacturing facility in Singapore in the Tuas Biomedical Park. The site contains two buildings, one dedicated to producing Lucentis, a treatment for wet age-related macular degeneration, while the other will make Avastin, a targeted cancer therapy. Both projects were initiated by Genentech, now a wholly owned subsidiary of Roche. More details...

Stock Symbol: (SW: RO)